National Cancer Institute (NCI): Glioma trials

The registry lists 112 Glioma studies with National Cancer Institute (NCI) as lead sponsor. 3 are open to participants now and 52 have results posted.

Phase 1 61Phase 2 60Phase 3 1No phase 8(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Brachytherapy in Treating Patients With Recurrent Malignant GliomaCompletedNCT00045474Phase 1
• CC-5013 in Treating Patients With Recurrent GliomaCompletedNCT00036894Phase 1
• Genetic Analysis of Brain TumorsTerminatedNCT00031538
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Atrasentan in Treating Patients With Progressive or Recurrent Malignant GliomaCompletedNCT00017264Phase 1
• Karenitecin in Treating Patients With Recurrent Malignant GliomaCompletedNCT00014521Phase 1
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or LymphomasCompletedNCT00012181Phase 1
• Natural History of Patients With Brain and Spinal Cord TumorsCompletedNCT00009035
• Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent GliomaCompletedNCT00005976Phase 2
• O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant GliomaCompletedNCT00004892Phase 1
• Carmustine in Treating Patients With Recurrent Malignant GliomaCompletedNCT00004028Phase 1
• Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem GliomaCompletedNCT00003909Phase 1